Lannett Announces Underwriters’ Exercise of Over-Allotment Option
2010年12月29日 - 3:07AM
ビジネスワイヤ(英語)
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic
pharmaceuticals, today announced that, in connection with its
previously announced underwritten registered public offering , the
underwriters have exercised in full their over-allotment option to
purchase an additional 750,000 shares of common stock. The
over-allotment option was granted in connection with the public
offering by Lannett of 2,500,000 shares of common stock and a
selling stockholder of 2,500,000 shares of common stock at $5.00
per share, which closed on December 17, 2010.
The net proceeds to Lannett from the sale of the over-allotment
shares, after the underwriting discounts and commissions and
estimated offering expenses payable by Lannett, are expected to be
approximately $3.5 million, bringing the aggregate net proceeds of
the offering to $14.95 million.
Oppenheimer & Co. and Roth Capital Partners acted as the
co-book running managers for the public offering.
The securities described above were sold in the offering by
Lannett and the selling stockholder pursuant to a “shelf”
registration statement on Form S-3, Registration Number 333-162318,
previously filed with the Securities and Exchange Commission (SEC)
and declared effective by the SEC on November 20, 2009. A
prospectus supplement related to the offering dated December 14,
2010 and filed with the SEC on December 15, 2010 is available on
the SEC’s web site at http://www.sec.gov. The prospectus supplement
and accompanying base prospectus may be obtained by sending a
request to Oppenheimer & Co. Inc., Attention: Syndicate
Prospectus Department, 300 Madison Avenue, 5th Floor, New York, NY,
10017, Telephone number: (212) 667-8563, Email:
EquityProspectus@opco.com. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures,
packages, markets and distributes generic pharmaceutical products
for a wide range of indications. For more information, visit
Lannett Company’s website at www.lannett.com.
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Any such statements, including, but not limited to,
Lannett’s expectations regarding the completion, timing and size of
its public offering, whether expressed or implied, are subject to
risks and uncertainties which can cause actual results to differ
materially from those currently anticipated due to a number of
factors which include, but are not limited to, risks and
uncertainties associated with market conditions, and other risk
factors discussed in the company’s Form 10-K and other documents
filed with the Securities and Exchange Commission from time to
time. These forward-looking statements represent the company's
judgment as of the date of this news release. The company disclaims
any intent or obligation to update these forward-looking
statements.
London Clubs (AMEX:LCI)
過去 株価チャート
から 6 2024 まで 7 2024
London Clubs (AMEX:LCI)
過去 株価チャート
から 7 2023 まで 7 2024